Rituximab Seen As RA Breakthrough A recent clinical study has revealed that rituximab (marketed as Rituxan), a therapeutic antibody that selectively targets the bodys B-cells, which are thought to play a key role in inflammatory rheumatoid arthritis, may be a significant breakthrough for RA sufferers. The study encompassed 11 countries and included 161 patients with moderate-to-severe, long-standing (average duration 10.4 years) RA who had failed to respond to methotrexate or various disease-modifying antirheumatic drugs (DMARDs). Two…
To continue reading this article or issue you must be a paid subscriber.
Sign in
